New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export HIND’s income statement to Excel — free account
Vyome Holdings, Inc.
HINDVyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.
- Revenue
- +67.6%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
1.20
0.25
−17.24%
Follow HIND
Alert me
Vyome Holdings, Inc. (HIND) news
Stories the last two months, newest first
More headlines
- Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School Business Wire
- Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market Business Wire
- Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
- Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
- Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
- Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet Business Wire
- Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity Business Wire
- Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026 Business Wire
- Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 Business Wire
- Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... GuruFocus.com
- Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase Business Wire
- Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company Business Wire
- Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity Business Wire
- Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months Business WireSimply Wall St.Simply Wall St.
- Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results Business Wire
- BC-Most Active Stocks Associated Press Finance
- Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study Business Wire
- We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate
- Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company Business Wire
- Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
- Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program Business Wire
- Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing Business Wire
- Vyome Holdings Announces Results of Annual Shareholder Meeting Business Wire
- Vyome Holdings Acquires MIT AI Spinout Oculo Health
- Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity Business Wire
- Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
- Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity Business Wire
- Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio
- Vyome Announces Strategic Review of Livechain (OTCID: LICH) Business Wire